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RNA interference is a powerful tool for studying gene
function, however, the reproducible generation of
RNAi transgenicmice remains a significant limitation.
By combining optimized fluorescence-coupled
miR30-based shRNAs with high efficiency ES cell
targeting, we developed a fast, scalable pipeline for
the production of shRNA transgenic mice. Using
this system, we generated eight tet-regulated shRNA
transgenic lines targeting Firefly and Renilla lucifer-
ases, Oct4 and tumor suppressors p53, p16INK4a,
p19ARF and APC and demonstrate potent gene
silencing and GFP-tracked knockdown in a broad
range of tissues in vivo. Further, using an shRNA tar-
geting APC, we illustrate how this approach can
identify predicted phenotypes and also unknown
functions for a well-studied gene. In addition,
through regulated gene silencing we validate APC/
Wnt and p19ARF as potential therapeutic targets in
T cell acute lymphoblastic leukemia/lymphoma and
lung adenocarcinoma, respectively. This system
provides a cost-effective and scalable platform for
the production of RNAi transgenic mice targeting
any mammalian gene.INTRODUCTION
Genetically engineered mice are invaluable tools for under-
standing biology and disease. Traditionally, manipulation of
gene expression in the mouse has relied on either the overex-pression of cDNAs or modification (deletion/knockin) of endoge-
nous genes using homologous recombination (Capecchi, 2005).
However, these approaches require a high investment to
produce functional genetically-engineered mice. The develop-
ment of site-specific recombination systems has added versa-
tility to these mouse-modeling strategies, allowing for spatial
and temporal control of gene activation or inactivation. Still,
such approaches are not reversible and remain time-consuming
and expensive.
RNA interference (RNAi) exploits an endogenous mechanism
of gene regulation that can be adapted to suppress gene expres-
sion in vivo (Hemann et al., 2003), and in principle provides
a fast and inexpensive alternative to conventional knockout
approaches. Potent RNAi-mediated gene silencing can be
induced by short hairpin RNAs (shRNAs) embedded within
a natural microRNA (miRNA) backbone (Dickins et al., 2005).
Importantly, in contrast to traditional gene targeting, shRNA
expression systems act without modifying the genomic locus
of the target and are, as such, reversible.
Several reports document that shRNA transgenic mice can be
used to study gene function in vivo (Dickins et al., 2007; Seibler
et al., 2007), although currently this approach is not widely used
because the reliable generation of such animals remains a signif-
icant technical challenge. Traditional transgenesis by pronuclear
DNA injection or viral transduction of zygotes or embryonic stem
(ES) cells have been used (Dickins et al., 2007; Rubinson et al.,
2003; Ventura et al., 2004) but generally give rise to animals
with highly variable knockdown. Gene targeting by homologous
recombination overcomes these drawbacks but relies on rare
events.
Here, we set out to address and optimize virtually all aspects of
producing shRNA-transgenic mice with the purpose of creating
a rapid, flexible and scalable platform to reduce the time, cost
and variability associated with developing such strains. WeCell 145, 145–158, April 1, 2011 ª2011 Elsevier Inc. 145
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Figure 1. TRE-Driven shRNAmirs Targeted to the ColA1 Locus Can Drive Robust DOX-Dependent Gene Knockdown in ES Cells
(A) Schematic diagram comparing the TGMP, TMGP and TMP retroviral vectors.
(B) Western blot analysis of p53.1224 infected tTA-expressing MEFs using TGMP, TMGP, and TMP retroviral vectors.
(C) Schematic diagram of the pCol-TGM vector. Coelectroporation of pCol-TGM and pCAGS-Flpe recombinase promotes integration and confers hygromycin
resistance.
(D) (Top) Representative luminescent images of two independent clones containing luc.1309/R26-rtTA. Cells were infected with MSCV-Luciferase and 48h post
infection cultured with or without DOX for 4 days. (Bottom) Quantification of luciferase activity. Error bars represent SEM, n = 2.
(E) Western blot analyses of DOX-treated ES cell clones containing R26-rtTA and luc.1309, p53.1224, Oct4.468, or APC.9365.
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reasoned that an ideal systemwould provide potent and regulat-
able gene silencing, trackable shRNA expression, be econom-
ical, high throughput and adaptable to allow constitutive and
tissue-specific gene knockdown. To achieve these goals, we
combined optimized fluorescence-coupled shRNA technology
with an Flp/FRT recombinase-mediated cassette exchange
(RMCE) strategy (Hochedlinger et al., 2005) to generate a system
for the production of single-copy, tet-regulatable shRNA trans-
genic ES cells and mice. This system is modular, flexible and
includes: (1) a targeting construct developed as a recipient
vector for any miR30-based shRNA and (2) an expression
cassette whereby shRNA expression is linked to a fluorescent
reporter, enabling easy tracking and isolation of cells. We
show that this system can be used to efficiently induce gene
silencing in ES cells, ex vivo cultured cells and embryonic and
adult tissues of the mouse, as well as reveal known and novel
phenotypes and validate therapeutic targets in vivo. Together,
this platform provides both a high throughput and cost effective
way to spatially, temporally and reversibly control endogenous
gene expression in mice.RESULTS
Generation of a Targeting Construct
To develop a versatile shRNA targeting construct, we sought to
construct an inducible, miR30-based expression cassette con-
taining a fluorescent reporter of shRNA expression. Wemodified
the retroviral doxycycline (DOX) inducible shRNA vector TMP,
(Dickins et al., 2007) targeting the tumor suppressor Trp53 by
inserting GFP either upstream (TRE-GFP-miR30-pgkPuro –
TGMP) or downstream (TRE-miR30-GFP-pgkPuro – TMGP) of
the miR30 cassette (Figure 1A). The presence of a GFP ‘‘spacer’’
between the TRE promoter and the shRNA (TGM) not only al-
lowed robust expression of GFP to serve as a reporter for shRNA
expression but also enhanced p53 knockdown in comparison to
the TMP and TMGP vectors (Figure 1B) (Stegmeier et al., 2005).
To enable efficient generation of targeted ES cells harboring
a single DOX-regulatable GFP-shRNA, we adapted the ColA1
Flp/FRT recombinase-mediated targeting system previously
described by Jaenisch and colleagues (Beard et al., 2006).
Pre-engineered ‘KH20 ES cells contain an FRT-hygro-pA
‘‘homing’’ cassette downstream of the ColA1 gene (hereafter
referred to as CHC), as well as a reverse tet-transactivator
(rtTA) targeted to the Rosa26 locus (referred to as R26-rtTA).
Following coelectroporation of pCAGs-Flpe and an appropriate
targeting vector, Flpe-mediated recombination between the
FRT site at the ColA1 locus and those present on the targeting
vector (Beard et al., 2006) (outlined in Figure S1A, available on-
line) confers hygromycin resistance only if correctly integrated.
The highly stringent combination of site directed recombination
and drug selection selects for precise targeting and from our
experience, reduces the number of clones that need to be
screened by 50- to 100-fold.(F) Western blot analyses of p53.1224 and APC.9365 clones treated with DOX a
(G) Brightfield and immunofluorescence images of Oct4.468/R26-rtTA cells treat
See also Figure S1. Scale bars represent 25 mM.To generate the targeting construct, we modified the pBS31-
ColA1 vector (Beard et al., 2006) to facilitate cloning of shRNAs
into the TRE-GFP-miR30 (TGM) design (Figure 1C). Using this
targeting vector, ColA1-TGM Flp-In (hereafter referred to as
pCol-TGM), nearly every shRNA from the Hannon-Elledge
genome-wide library (Silva et al., 2005) or RNAi codex library
(Olson et al., 2006) can be inserted into the miR30 backbone in
a single cloning step. Following ES cell electroporation, hygro
selection and expansion of individual clones, cells were
screened for DOX-dependent GFP expression (outlined in Table
S1). Approximately 100% of dual-selected, hygromycin-resis-
tant-GFP-positive clones showed correct targeting by Southern
blot (Figure S1B). By contrast, transgenic cells derived by pronu-
clear injection typically showed several integrations (Figure S1C,
data not shown). We determined it was necessary to screen only
four clones for each transfected shRNA, allowing targeting of
many different shRNAs simultaneously with minimal effort.ColA1-Targeted shRNAs Enable Potent and Reversible
Knockdown in ES Cells
Using our workflow (Table S1), we generated several ES cell lines
harboring an shRNA targeting the firefly bioluminescence
reporter gene, luciferase (TG-luc.1309), to serve as a control.
We also produced ES clones with shRNAs targeting a number
of endogenous genes, including the pluripotency transcriptional
regulator, Pou5f1 (TG-Oct4.468) and the tumor suppressor
genes Trp53 (TG-p53.1224), Adenomatous Polyposis Coli
(TG-APC.9365 and TG-APC.3374), p19ARF (TG-p19.157), and
the transcript that encodes both p16INK4a and p19ARF (TG-p16/
p19.478).
To validate the effectiveness of single-copy shRNAs targeted
to the ColA1 locus, we confirmed knockdown in five indepen-
dently selected TG-luc.1309/R26-rtTA ES cell clones trans-
duced with a luciferase-expressing retrovirus by biolumines-
cence imaging (two representative clones shown in Figure 1D).
In addition, we measured strong suppression of endogenous
protein expression in selected TG-p53.1224/R26-rtTA, TG-
Oct4.468/R26-rtTA and TG-APC.9365/R26-rtTA ES cell clones
after DOX treatment and this knockdown was fully reversible
(Figures 1E and 1F). GFP expression was not detected in
untreated samples but strongly correlated with gene knockdown
(Figure 1E and Figure S1D) and thus provides a visual biomarker
of shRNA expression.
Knockdown of endogenous gene expression using RNAi was
associated with dramatic phenotypes in ES cells. Specifically,
TG-p53.1224/R26-rtTA cells showed marked resistance to the
DNA damaging agent Adriamycin following p53 suppression by
DOX addition (Figure S1E), whereas, TG-Oct4.468/R26-rtTA ES
cells treatedwithDOXunderwent differentiation toward a tropho-
blast lineage (Figure 1G and Figure S1F). These phenotypes
precisely reflect what has been observed in cells harboring the
respective gene deletions (Lowe et al., 1993; Nichols et al.,
1998) and illustrate that expression of a single shRNA transgenes indicated and then shifted to normal media for 2 or 4 days prior to harvest.
ed with DOX for 7d. Cells were stained with antibodies as indicated.
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Figure 2. Reversible Knockdown of Gene Targets in Primary Mouse Embryonic Fibroblasts Derived from ColA1-TGM ES-Cell-Derived Mice
(A) Bioluminescence imaging of luc.1309 and luc.1309;R26-rtTA MEFs infected withMSCV-luciferase. MEFs were treated with DOX, then shifted into DOX-free
media as indicated.
(B) Quantification of the bioluminescence signal to assess luciferase knockdown. Error bars represent SEM, n = 2.
(C and D) Western blot analysis of MEFs harvested from a cross between C57BL/6 WT mice and p19.157;R26-rtTA or p53.1224;R26-rtTA founder mice, treated
with DOX as indicated.
(E) Colony formation assay of R26-rtTAMEFs containing either luc.1309, p53.1224 or p19.157 plated at low density and cultured with or without DOX for 12 days.
(F) MEFs pretreated with DOX for 10d were plated at low density and cultured with or without DOX for 12 days.
(G) Proliferation of DOX-treated TG-luc.1309;R26-rtTA and TG-APC.9365;R26-rtTA MEFs relative to off-DOX populations. Error bars represent SEM, n = 4.
See also Figure S2.at the ColA1 locus can induce significant gene knockdown and
mimic loss of function phenotypes.
ColA1-Targeted shRNAs Enable Potent and Reversible
Gene Suppression In Vitro
We next generated fully ES cell-derived transgenic mice using
tetraploid embryo complementation, an approach that reduces
time and cost by eliminating the need to screen founder lines
for germline transmission. To test the potency and reversibility
of knockdown in each transgenic line, we isolatedMEFs carrying
the TG-shRNA and R26-rtTA alleles andmeasured target protein
expression. As seen in ES cell clones, DOX treatment induced148 Cell 145, 145–158, April 1, 2011 ª2011 Elsevier Inc.significant depletion of luciferase activity in double transgenic
(TG-luc.1309/R26-rtTA) but not single transgenic (TG-luc.1309)
MEFs (Figures 2A and 2B). Moreover, luciferase activity was
recovered upon DOX withdrawal, indicating the knockdown
was fully reversible. Similarly, in MEFs derived from each of the
TG-p53.1224, TG-APC.9365, TG-p19.157, and TG-p16/
p19.478 shRNA founder lines we observed substantial and
reversible DOX-dependent protein knockdown (Figures 2C and
2D and Figures S2A and S2B). In TG-APC.9365 MEFs, gene
silencing led to a significant and reversible induction of down-
stream signaling, as measured by expression of the Wnt target
gene Axin2 (Figure S2C).
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(A) Scatter plot representing the normalized expression
of the 319 most abundant miRNAs from DOX-treated
and untreated TG-luc.1309/R26-rtTAMEFs. R2 correlation
coefficient excludes TG-luc.1309 sequence reads.
(B) Number of normalized reads obtained for the top 20
miRNAs and luc.1309 expressed in MEFs.
See also Figure S3.Deletion of several of the genes targeted using transgenic
shRNAs affects proliferation in MEFs. Like the corresponding
null mutants, suppression of either p53 or p19ARF promoted
immortalization as demonstrated by their ability to form colonies
when plated at low density (Figure 2E) (Lundberg et al., 2000).
Additionally, TG-p53.1224/R26-rtTA and TG-p19.157/R26-rtTA
MEFs pretreated with DOX lost their ability to form colonies
when removed from DOX-containing media, indicating that DOX
withdrawal restores tumor suppressor function and reverts the
immortalized phenotype (Figure 2F). Conversely, induction
of APC.9365 in MEFs caused a progressive proliferation arrest
(Figure 2G) consistent with what has been described following
activation of Wnt signaling in MEFs via overexpression of a stable
mutant b-catenin (Damalas et al., 2001). As has been noted for
cells harboring gene deletions, suppression of p19ARF by RNAi
enabled the rapid expansion of isolated pre-B cells in vitro (data
not shown), andsuppressionofp53dramaticallyenhancedcolony
formation of isolated hepatic stellate cells (V. Krizhanovsky, P.P.,
and S.W.L., unpublished data). Thus, cells derived from distinct
tissues showconsistent, efficient and reversible gene knockdown
that is associated with predicted phenotypic changes.
Transgenic shRNAs Do Not Impair Normal MicroRNA
Processing
Studies suggest that high levels of shRNA expression can cause
saturation of the miRNA processing machinery (Grimm et al.,
2006). To determine whether shRNA expression in our system
disrupts endogenous miRNA processing, we measured the
abundance of all mature miRNA species using high-throughput
sequencing. Small RNA libraries (Malone et al., 2009) prepared
from single (TG-luc.1309) and bitransgenic (TG-luc.1309/R26-
rtTA) MEFs showed few or no changes in the expression or
relative proportions of endogenous miRNAs. (Figure 3 and Fig-
ure S3). As expected, we observed a substantial (25-fold)
DOX-dependent induction of the synthetic luc.1309 mature
miRNA species (Figure 3). We also noted a basal level of
luc.1309 expression in the absence of DOX and rtTA, reflecting
low-level DOX- and rtTA-independent leakiness from the TRE
promoter in MEFs that is cell type specific (data not shown).Cell 14Importantly, this potential leakiness does
not cause significant gene knockdown in
TG-p53.1224, TG-p19.157, TG-p16/p19.478 or
TG-APC.9365 MEFs (Figures 2C and 2D and
Figure S2). These results are consistent with
reports that miR30 based shRNAs show
reduced general toxicity compared to other
RNAi triggers (McBride et al., 2008) and demon-strate that DOX-regulated shRNAs expressed from the ColA1
locus allow reversible silencing of gene expression without
disrupting endogenous miRNA processing.
ColA1-Targeted shRNAs Enable Potent and Reversible
Gene Suppression In Vivo
To evaluate the dynamics of reversible gene silencing in vivo, we
bred mice that express luciferase from the endogenous Rosa26
promoter to TG-luc.1309/R26-rtTA mice to produce triple trans-
genics (TG-luc.1309/R26-rtTA/R26-luciferase, or shluc/R/RL)
and littermate controls (shluc/RL). Rosa26 expression is report-
edly high in embryonic tissues (Soriano, 1999), therefore, we first
tested knockdown in E17.5 embryos. Triple transgenic embryos
showed marked induction of GFP expression and 75% knock-
down of luciferase relative to controls (Figures 4A and 4B),
consistent with the maximal level of knockdown we observed
in ES cells and transgenic MEFs with this shRNA (Figure 1D
and Figures 2A and 2B).
We next measured the dynamics of luciferase silencing longitu-
dinally in the skin of triple transgenic mice. After 4 days of DOX-
treatment, shluc/R/RL animals showed significant luciferase
knockdown (and high GFP expression) relative to untreated triple
transgenic mice (Figures 4C and 4D). This suppression was
reversible, with loss of GFP and increased luciferase expression
4 days following DOX withdrawal and after 12 days Luciferase
activity returned to basal levels. To evaluate knockdown in addi-
tional tissues we imaged individual organs for GFP and biolumi-
nescence. Consistent with previous reports (Beard et al., 2006),
weobservedsignificant variation in the level ofR26-rtTA-mediated
GFP induction between different organs (Figures 4E and 4F and
Figures S4A and S4B). Importantly, tissues that displayed strong
induction (>20-fold) of GFP expression (skin, intestine, thymus,
and liver) showed luciferase knockdown approaching the
maximal potency of this shRNA in vitro (Figure 4 and Figure S4C).
A Tet-Transactivator Line that Enables Efficient
Knockdown in a Broad Range of Adult Tissues
During the course of our in vivo analyses we noted that the
presence of two R26-rtTA transgenic alleles increased the5, 145–158, April 1, 2011 ª2011 Elsevier Inc. 149
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Figure 4. Reversible GFP-marked DOX-Dependent Knockdown in Live Animals
(A) GFP and bioluminescent images of E17.5 TG-luc.1309;R26-rtTA;Rosa-luciferase (shluc/R/RL) embryos sacrificed from pregnant females treated with or
without DOX.
(B) Relative GFP intensity and (C) bioluminescence between shluc/RL and shluc/R/RL embryos. Error bars represent SEM, n = 7.
(D) In vivo bioluminescent time course imaging of TG-luc.1309;R26-rtTA;Rosa-luciferase (shluc/R/RL) triple transgenics and controls. Animals were treated with
or without DOX for 4 days, then removed from treatment.
See also Figure S4.
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DOX-dependent expression of GFP-shRNAs relative to a single
allele (not shown). This indicated that, not only was rtTA expres-
sion from theRosa26 promoter tissue restricted (Figure S4), but it
was limiting for maximal expression from the TRE promoter in
many adult tissues. To address this limitation, we sought to
develop a stronger, more ubiquitous, strain expressing a highly
sensitive reverse tet-transactivator (rtTA3) downstream of the
strong CAG promoter (Niwa et al., 1991). After characterizing a
strain that contained a single genomic insertion of CAG-rtTA3
(data not shown), we generated triple transgenic mice carrying
TG-luc.1309/CAG-rtTA3/R26-luciferase (shluc/C3/RL) and
imaged individual organs for knockdown (Figure 4G and Fig-
ure S4D). In contrast to shluc/R/RL mice, shluc/C3/RL triple
transgenics showed robust induction of GFP in almost all tissues
examined and, accordingly, tissues that expressed high levels of
GFP displayed knockdown of luciferase to levels consistent
with the intrinsic potency of this shRNA (Figures 4G and 4H
and Figures S4D–S4F). These results establish CAG-rtTA3 as
a broadly useful tet-transactivator strain and demonstrate that
strong expression from the TRE promoter at the ColA1 locus is
possible in almost all adult mouse tissues.
Studying Gene Function during Embryonic and
Postnatal Development: Reversible and Irreversible
Consequences of Hyperactive Wnt Signaling
We reasoned that the inducibility and reversibility of gene
silencing enabled by our system would facilitate the study of
gene function during defined windows of development and
disease, particularly for those genes whose inactivation results
in embryonic lethality, such as APC (Moser et al., 1995). Similarly
we observed embryonic lethality following early (E0.5) depletion
of APC (data not shown). While conditional deletion strategies
with various tissue-specific Cre recombinases have enabled
conditional deletion at later stages of development in specific
tissues (for example, see Colnot et al., 2004; Kuraguchi et al.,
2006; Sansom et al., 2004) we examined the consequences of
global APC knockdown at different developmental stages by
simply varying the timing of DOX treatment (Figures 5A and
5B). Although untreated and TG-luc.1309/R26-rtTA animals
developed normally (Figure 5C, not shown), TG-APC.9365/
R26-rtTA bitransgenic embryos DOX-treated at E8.5 displayed
prominent hydrops fetalis (pronounced fetal edema) (Figure 5C
and Figure S5A) and died prior to birth (n = 14). At E14.5 and
E18.5, DOX-treated embryos revealed a severe delay or
absence in growth and endochondral ossification of multiple
skeletal elements (spine, ribs, and limbs) (Figure 5C and Fig-
ure S5B) identical to the phenotype recently reported using
skeletal specific mutation of APC (Miclea et al., 2009).
A theoretical advantage of our system is the potential for
interrogating gene/pathway function during defined develop-
mental windows by controlling gene repression and reactivation.
To test the feasibility of this approach, we studied the impact of
transient APC suppression during embyogenesis. shAPC
embryos pulse-treated with DOX for 4 days (E8.5 to E12.5)
showed no edema and marked recovery of some bone growth
(ribs, spine, and skull), although both hind and forelimb develop-
ment remained severely stunted (Figure 5C), especially when
knockdown was driven by an additional R26-rtTA allele (Fig-ure S5C). Interestingly, DOX-pulsed embryos also developed
extra digits (total 5–9) that were largely unsegmented and ap-
peared duplicated along their length (Figure S5D). These data
imply that regulation of Wnt signaling by APC dictates the timed
development and differentiation of different skeletal elements
during embryogenesis and that even transient disruption to
APC function can cause irreversible defects in tissue patterning.
To examine whether our system could be used to study post-
natal development, we avoided the consequences of APC
suppression in utero by delaying DOX treatment until near birth.
Although shAPC (9365 or 3374) induction 1–2 days prior to birth
was tolerated, it resulted in postnatal defects including stunted
development of the snout and runting (Figure S5E, not shown),
consistent with tissue restricted APC excision during mid-
embryogenesis (Kuraguchi et al., 2006). Continued APC
silencing for 6 weeks (initiated at birth or 4-6 weeks of age)
promoted excessive hair growth (Figure 5D) while long-term
DOX treatment beyond 20 weeks resulted in progressive hair
loss and significant disruption to the normal structure of the
hair follicles (Figures 5E and 5F). Interestingly, reactivation of
APC after 4 weeks of DOX-treatment prevented eventual hair
loss but could not revert the development of a stunted snout
(data not shown). In contrast, dysregulation of hair follicle func-
tion was reversible, as re-expression of APC in largely hairless
mice promoted rapid recovery of pelage (Figure 5E and Fig-
ure S5F). In all, these data demonstrate that APC and the precise
control of Wnt is crucial at many stages of mammalian embry-
onic and postnatal development and define both permanent
and reversible consequences of APC loss. Such insights go
beyond what could be obtained through conditional knockout
approaches and, in principle, conceptually similar approaches
could be applied to study any endogenous gene.
Studying Gene Function in Disease Initiation
and Maintenance: APC Suppression Is Required
for the Initiation and Maintenance of T-ALL
Perhaps one of the more interesting potential applications of
inducible shRNA transgenics is to study disease associated
with loss of gene function, where reversibility of gene suppres-
sion would determine whether restoring gene function would
ameliorate disease symptoms and help pinpoint therapeutic
targets. Activation of the Wnt pathway, often through deregula-
tion of APC, is one of the most frequent events in human cancers
(Clevers, 2006) and represents a potential target (Gunther et al.,
2003). To explore this possibility, shAPC/R26-rtTA mice were
maintained on DOX from 4–6 weeks of age, until they showed
signs of disease. All moribund mice presented with lymphoma
with a median survival of 7.4 (TG-APC.9365) and 5.3
(TG-APC.3374) months (Figures 6A and 6B). Primary leukemia/
lymphomas were detected in the thymus and lymph nodes
(Figure 6B, data not shown). Additionally, secondary organs
(e.g., liver) showed minor infiltration of lymphoblastic disease
(Figure 6B) and were transplantable into secondary recipients
(Figure 6 and Figure S6). In all cases examined (7/7) leukemia/
lymphomas expressed both CD4 and CD8 on their surface (Fig-
ure 6C), indicative of uncommitted T-lymphoid progenitors.
Hence, the disease had many features of human T cell acute
lymphoblastic leukemia/lymphoma (T-ALL), a disease in whichCell 145, 145–158, April 1, 2011 ª2011 Elsevier Inc. 151
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Figure 5. APC Loss Disrupts Embryonic and Postnatal Development
(A) Western blot of whole protein lysates from E10.5 embryos on DOX for 2 days and (B) E14.5 embryos on DOX for 6 days.
(C) GFP and brightfield images of embryos treated with DOX from E8.5 or pulsed with DOX from E8.5-E12.5. Arrows indicate fluid accumulation along the dorsal
ridge and defects in limb and digit development at E12.5 and E14.5. Alcian blue and Alizarin red stained skeletons from E18.5 embryos.
(D) Representative photographs of TG-luc.1309/R26-rtTA, TG-APC.3374/R26-rtTA and TG-APC.9365/R26-rtTA double transgenic mice on DOX for 6 weeks.
(E) Representative photographs of luc.1309, APC.3374, and APC.9365 treated with DOX for 20 weeks and then removed from DOX-treatment for 6 weeks.
(F) H&E sections of skin taken from luc.1309/R26-rtTA and TG-APC.9365/R26-rtTA double-transgenic mice treated with DOX for 6 weeks, 20 weeks, and
20 weeks on DOX / 6 weeks off DOX as indicated. Scale bars represent 100 mm.
See also Figure S5.Wnt signaling has recently been associated with (Yang et al.,
2005).
Previous studies using overexpressed transgenes suggest
that hyperactive Wnt signaling is required for the maintenance
of some murine cancers (Gunther et al., 2003). However, our
shAPC transgenic enabled us, for the first time, to explore the
role of APC suppression and physiological Wnt pathway dereg-152 Cell 145, 145–158, April 1, 2011 ª2011 Elsevier Inc.ulation in tumor maintenance. Five weeks post-transplant, when
mice showed 10% GFP-positive leukemia cells in the periph-
eral blood, animals were randomized into two cohorts and moni-
tored for disease progression in the presence and absence of
DOX (Figure 6D and Figure S6A). Animals that remained on
DOX became moribund within 1–2 weeks, showing massive
disease infiltration into secondary organs (Figure 6E, Figure S6B,
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Figure 6. APC Loss Is Required for the Maintenance of T Lymphoblastic Leukemia/Lymphoma
(A) Kaplan Meier analysis of R26-rtTA/TG-shRNA double transgenic mice treated continually with DOX from 4–6 weeks of age.
(B) Fluorescent image of TG-APC.9365/R26-rtTA animals with GFP positive tumor in the thymus. All analyzed animals that became moribund developed T
lymphoblastic leukemia/lymphoma apparent in the thymus, lymph nodes (data not shown), and liver. Scale bars represent 50 mm.
(C) Representative flow cytometry plots of cells isolated from primary lymphomas and stained for surface markers: Thy1, CD4, and CD8.
(D) GFP positive (left) and CD4/CD8 double positive cells in the peripheral blood of SCID mice transplanted with TG-APC.3374 lymphoma following the
DOX-switch. Error bars represent SEM.
(E) H&E stained sections of the liver (upper) and bone marrow (femur – lower) in mice on DOX or removed from DOX for 2 weeks (off DOX). Scale bars represent
50 mm (liver) and 20 mm (femur).
(F) Kaplan Meier analysis of SCID mice transplanted with TG-APC.3374 primary lymphoma. Graph is plotted from the time of DOX-switch (5 weeks after
transplant).
See also Figure S6.and data not shown). In contrast, ‘‘off-DOX’’ animals showed
a rapid clearance of GFP+ and CD4+/CD8+ cells from the periph-
eral blood and secondary organs (Figures 6D and 6E), leading to
a significant survival benefit (Figure 6F, p = 0.003). Strikingly, one
animal that presented with lymphoma associated hind limb
paralysis at 4 weeks, regained normal limb function only
3 days following DOX withdrawal (Movies S6A and S6B). Impor-
tantly, 2/5 animals showed relapse of lymphoblastic disease
4 weeks after DOX withdrawal. Such relapsed cancers were
entirely GFP negative and showed strong re-expression of
APC (Figure S6C), suggesting that the disease can eventually
become independent of APC suppression. These data demon-
strate that APC suppression is required for tumor maintenance,
validate the Wnt pathway it controls as a therapeutic target in
T-ALL and provide a system for studying resistancemechanisms
to Wnt antagonists. More generally, they illustrate that the
shRNA approach can effectively recapitulate disease etiology
predicted from genetic mouse models and rapidly determine
whether the pathology depends on this initiating lesion.
Studying Genetic Modifiers of Disease: p19ARF
Suppression Promotes the Initiation and Maintenance
of KrasG12D-Induced Lung Cancer
We envisioned that our shRNA transgenic platform would facili-
tate the analysis of genes that modulate disease onset andprogression in a variety of pre-existing mouse models of human
disease. As a proof-of-principle, we took advantage of a pre-ex-
isting mouse strain harboring a latent oncogene Kras (G12D)
allele, in which the ras oncogene can be activated by intranasal
injection of adenoviral Cre (adeno-Cre) leading to the develop-
ment of lung adenocarcinoma (Jackson et al., 2001). Studies
suggest that hypermethylation of the ARF tumor suppressor
occurs in approximately 30% of human nonsmall lung cancers
(Ozenne et al., 2010) and that gene deletions targeting ARF
can cooperate with oncogenic Kras to induce lung adenocarci-
noma in mice (Fisher et al., 2001). To test whether gene suppres-
sion of ARF using RNAi could produce similar results, we
produced mice carrying 4 alleles: (1) TG-p19.157, (2) LSL-
KrasG12D, (3) rCCSP-rtTA (rat Clara cell secretory protein), and
(4) R26-LSL-luciferase. We also used an additional shRNA trans-
genic line targeting Renilla luciferase (TG-Ren.713) (Zuber et al.,
2010), a control shRNA that does not repress the luciferase
reporter.
Transgenic mice harboring either TG-p19.157 or TG-Ren.713
and rCCSP-rtTA/LSL-KrasG12D/R26-LSL-luciferase (referred to
as shARF/Kras or shRen/Kras respectively), were inoculated
with adenoviral Cre and simultaneously treated with DOX to
induce the p19ARF shRNA. As expected, luciferase imaging
showed that shARF/Kras animals exhibited markedly increased
tumor burden compared to shRen/Kras and Kras alone controlsCell 145, 145–158, April 1, 2011 ª2011 Elsevier Inc. 153
(Figure S7A) and, by 12–14 weeks post infection, shARF/Kras
DOX-treated mice displayed rapid shallow breathing, cachexia
and an increase in both size and number of tumor nodules in
the lung (Figures S7B, S7C, and S7D). Histopathological anal-
yses revealed pulmonary neoplasias (Figure 7E) similar to those
seen in p19ARF knockoutmodels combinedwith KrasG12D activa-
tion (Fisher et al., 2001), while controls showed predominantly
hyperplastic growth with rare noninvasive lung adenomas (data
not shown). The increased tumor burden in shARF/KRas mice
resulted in significantly reduced survival (p < 0.0001) compared
to shRen/Kras and Kras controls (Figure 7A). Thus, gene
suppression using transgenic RNAi can recapitulate a null
phenotype even in a complex multiallelic system.
As described above, a unique feature of our platform is the
ability to manipulate gene expression after disease onset. In
the case of shARF/Kras lung carcinomas, this feature allowed
us to explore the potential of an experimental strategy currently
undergoing clinical development. Drugs targeting DNA methyl-
transferases (DNMTI) and histone deacetylase inhibitors (HDACI)
have been put forward as a therapeutic strategy to reactivate
tumor suppressor genes in established tumors, and we
reasoned the effects of ARF reactivation in lung carcinomas
would point toward a subset of expected ‘‘on-target’’ effects of
such agents. Therefore, shARF/Kras animals with detectable
disease were withdrawn from DOX treatment. After two weeks,
ARF reactivation coincided with a massive induction of
cleaved-caspase 3 (Figure 7B and Figure S7F) and measurable
decrease in bioluminescent signal (Figure S7A), suggesting
that a p19ARF-induced apoptotic response can promote tumor
regression in KRasG12D driven lung cancer. Histological analyses
showed clear tumor regression within DOX-removed animals
(data not shown), which likely contributed to a significant survival
benefit following ARF re-expression (Figure 7A, p < 0.0001)
compared to those animals continually treated with DOX (Fig-
ure 7A). However, DOX-removed shARF/Kras mice died at
a similar time as Kras controls (Figure 7A), perhaps owing to a
subset of mutant tumors that failed to reactivate ARF or acquired
mutations in the rtTA allele. Consistent with the latter, upon sacri-
fice, some lung tumors were GFP positive, indicating continued
expression of the shRNA. Nonetheless, these results are consis-
tent with recent reports describing the effects of p53 reactivation
in lung carcinomas (Feldser et al., 2010; Junttila et al., 2010), and
imply that reversing ARF silencing in lung adenocarcinomas will
have a therapeutic benefit. More broadly, they illustrate how
transgenic RNAi can be effectively employed to control gene
regulation in complex genetic models.
Accelerating the Analysis of Complex Models
of Disease Using Conditional RNAi
The large volume of information emerging through genomic and
genetic screens has implicated many new genes in human
disease. While our shRNA transgenic platform provides one
strategy to rapidly explore the biology of such genes in vivo,
the time and cost associated with introducing each new shRNA
transgenic tomore complex genetic backgrounds remains a limi-
tation. In an attempt to rapidly producemicewithmultiple alleles,
recent work documents the utility of producing mice with
complex genotypes from ES cells engineered to harbor multiple154 Cell 145, 145–158, April 1, 2011 ª2011 Elsevier Inc.genetically engineered alleles (Zhou et al., 2010). We sought to
synthesize this strategy with our shRNA platform by exploring
the feasibility of rederiving ES cells from mice harboring the
shRNA targeting cassette together with other disease promoting
alleles. We reasoned that this ‘speedy’ strategy (Figure 7C)
would enable investigators to rapidly produce mice harboring
any naturally-occurring or engineered mouse alleles with any
inducible shRNA, thus bypassing slow and expensive breeding
regimes, particularly when interested in the effects of more
than one shRNA.
As a proof-of-principle using the lung adenocarcinoma model,
we rederived ES cell clones containing the four relevant alleles:
LSL-KrasG12D, rCCSP-rtTA, R26-LSL-luciferase and the ColA1
FRT ‘‘homing cassette’’ and targeted two clones with the
p19.157 shRNA as previously described (Figure 1A). ES cell-
derived mice and chimeras were successfully generated by
tetraploid embryo complementation or injection into C57BL/6
albino host blastocysts and ‘‘speedy’’ shARF/Kras mice were
treated with adeno-Cre. All speedy mice developed tumors
detectable by bioluminescence imaging 8 w.p.i. (n = 8) as antic-
ipated and showed rapid tumor regression in response to ARF
reactivation (Figure 7D). Additionally, histological examination
revealed that tumor multiplicity and size was significantly atten-
uated following DOX removal (Figures 7E and 7F). These data
precisely recapitulate the results produced through intercrossing
but at a fraction of the time and cost. With the system now in
place it can be used to examine the impact of virtually any
gene on Kras-induced lung cancer development and regression
without additional intercrossing. More generally, this approach
can be adapted to study any gene in any disease state that
can be modeled in the mouse, and is amenable to the simulta-
neous testing of many candidate disease-modulating shRNAs.
DISCUSSION
Transgenic RNAi offers a flexible and systematic alternative to
homologous recombination for studying gene function in vivo.
While RNAi cannot replace gene targeting in creating precise
genetic lesions, it enables fast, reproducible, and cost-effective
generation of transgenic mouse models with unique capabilities
for spatial, temporal, and reversible suppression of endogenous
genes. Here we set out to optimize every step in the production
and analysis of shRNA-transgenic mice by developing: (1) a
system that enables efficient ES cell targeting, enhanced gene
silencing, and fluorescence-coupled tracking of shRNA expres-
sion in vivo, and (2) an approach to rapidly combine shRNAs with
existing disease alleles. Importantly, the system is modular such
that it can be modified to incorporate alternate reporters (e.g.,
turboRFP, mCherry), tandem shRNA cassettes, or be adapted
for controlled expression of additional noncoding RNA species
(unpublished data). Additionally, we have recently developed
a systematic and high-throughput screening methodology to
identify the most efficient shRNAs targeting any given transcript
(Fellmann et al., 2011); these shRNAs can then be seamlessly
incorporated into the production of shRNA transgenic mice.
Together with the availability of optimized RNAi triggers, the
system provides a high throughput platform that streamlines
production of ES cells and transgenic mice harboring conditional
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Figure 7. Reversible Suppression of ARF in a Multiallele Disease Model Documents a Contribution to Tumor Maintenance
(A) Kaplan Meier analysis of Kras, shRen/Kras and shARF/Kras treated with Adeno-Cre and DOX at 4-6 weeks. Cohorts were randomized and followed with or
without DOX treatment, 8 w.p.i.
(B) Confocal microscopy images of 150 mm sections from lungs of shRen/Kras and shARF/Kras animals on DOX at 8 w.p.i. or off DOX for 2 weeks (10 w.p.i.).
Sections were stained with an antibody to detect ARF and DAPI. The scale bar represents 100 mm.
(C) The speedy mouse workflow to derive and retarget multiallelic ES cell clones from intercrossed mice.
(D) Bioluminescence images of shARF/Kras mice produced by the ‘speedy’ approach (C) and treated with Adeno-Cre and DOX at 5 weeks of age. At 8 w.p.i.,
cohorts were randomized and followed with or without DOX treatment for 2 weeks.
(E) Quantification of lesions in the lungs of ‘speedy’ shARF/Krasmice at 8 and 10 w.p.i. For each animal, area and multiplicity represent the mean scored across
10 H&E stained sections taken at 100 mm apart. Error bars represent SEM (left).
(F) Representative H&E stained sections of the lungs from mice in (D,E). Arrows mark lesions scored. The scale bar represents 1mm.
See also Figure S7.
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shRNAs, enabling exquisite control of endogenous gene expres-
sion in vivo.
RNAi-mediated gene silencing does not produce a complete
null situation and hence shRNA transgenics will not replace
the need for conditional knockout mice, at least in some settings.
Rather, we envision that this technology will provide a compli-
mentary approach when speed and scale are desirable—
a situation that may be increasing as biologists try to understand
the avalanche of information emerging from various genome
projects. We also envision that our system will enable the
evaluation of hypomorphic phenotypes reflective of many
human conditions and disease states and may be applicable
to the examination of potential drug targets and in this context,
the level and duration of gene suppression that can be tolerated
in vivo. Here we demonstrate the strength of our system for
investigating gene function in vitro and in vivo during multiple
stages of embryonic and postnatal development and disease
progression. Importantly, the ability to reversibly regulate gene
expression allowed us to explore the consequences of transient
APC loss during development and define a small window of
development where APC is essential for regulating skeletal
morphogenesis.
Using single andmultiallelic approaches, we also showed how
shRNA transgenic mice can be used to accurately model human
disease and, through gene reactivation, assess the potential of
therapeutic targeting strategies. Indeed, the system provides
the unique capability of genetically mimicking the action of
potential drugs whose action would likely be transient and
incomplete, enabling validation of drug targets and characteriza-
tion of drug toxicities in a manner that has not previously been
possible. Finally, further application of the multiallelic speedy
approach should provide a relatively high throughput platform
for in vivo characterization of candidate genes identified using
shRNA-based screens or genome-wide association studies
and will facilitate triaging and prioritizing drug targets in expen-
sive drug development programs.
Despite the advances shown here, the limited scope and
effectiveness of available tet-transactivator strains and the
paucity of shRNAs that act efficiently at single copy represent
two remaining barriers to achieving an ideal system. As a first
step toward addressing the former issue, we developed a
tet-transactivator strain (CAG-rtTA3) that provides stronger
and more widespread expression of TRE-regulated shRNAs
than any other strain we have tested, including R26-rtTA,
Actin-rtTA and CMV-rtTA (data not shown). Although some
organs, such as the brain, spleen and lung showed lower GFP
expression and reduced luciferase knockdown (see Figure S4),
we believe this is likely due to limited delivery of DOX to these
cells (in the case of brain) or sub-optimal rtTA expression rather
than inaccessibility of the targeted ColA1 locus. In fact, tissue-
specific expression of tet-transactivators in CCSP-rtTA and
Vav-tTA strains can promote effective ColA1-targeted shRNA
expression in lung epithelium (Figure 7) and B cells (data not
shown), respectively. It will be important to determine which of
the > 100 existing tet-transactivator strains (http://www.zmg.
uni-mainz.de) will provide sufficient tTA/rtTA expression for
effective knockdown and to develop additional robust and
versatile strains.156 Cell 145, 145–158, April 1, 2011 ª2011 Elsevier Inc.Webelieve that transgenic systems such as the one described
here have the potential to transform mammalian genetics.
Indeed, in lower organisms such as D. melanogaster and
C. elegans, the application of in vivo RNAi on a broad scale
has had an enormous impact on the ability of these models to
provide insights into the physiology of whole organisms in isola-
tion or in the context of other disease associated alleles. With
similar capabilities now achievable in mice, it should be possible
to rapidly explore all aspects of mammalian physiology and
provide clues to the molecular control of normal development,
aging, and disease. Accordingly, we have now implemented
a 96-well targeting format to enable paralleled production of
hundreds of ES cells and transgenic mice with inducible and
reversible, RNAi-mediated gene silencing. With this pipeline it
is now possible and indeed feasible, to develop single and
multiallelic shRNA transgenic animals to evaluate in parallel the
function of many mammalian genes.
EXPERIMENTAL PROCEDURES
Targeting Constructs and ES Cell Targeting
Details of targeting construct and shRNA cloning can be found in the Supple-
mental Information. Coelectroporation of 50 mg pCol-TGM with 25 mg pCAGs-
FLPe at 400 V and 125 mF was performed using two pulses in a Gene PulserII
(Bio-Rad, Hercules, CA). 36–48 hr post electroporation, GFPwasmeasured by
flow cytometry (Guava EasyCyte) to assess the electroporation efficiency.
Only cultures with > 10% GFP expression were maintained and selected in
140 mg/ml hygromycin. Clones were screened as indicated (Table S1).
Transgenic and Speedy Mice
Rosa26-LSL-luciferase females and Stra8-Cre males (Sadate-Ngatchou
et al., 2008) were crossed to produce RL mice. DOX was administered to
mice via food pellets (625mg/kg) from Harlan Teklad. The Cold Spring Harbor
Animal Care and Use Committee approved all procedures described in this
work. TG-shRNA transgenic mice were genotyped by genomic PCR using
shRNA-specific forward primers and a common reverse primer (Table S2),
yielding an 250-bp product. CAG-rtTA3 mice were generated using pronu-
clear injection and genotyped by PCR. rtTA3 Southern blots were performed
on genomic DNA digested with BamHI, using a probe covering the coding
region of rtTA3. Speedy mice were produced using ES cells rederived from
E3.5 blastocysts (Bryja et al., 2006).
Alcian Blue and Alizarin Red Skeletal Staining
E14.5–E18.5 embryos were euthanized and all skin was removed. Animals
were fixed in 95% ethanol for 24 hr, transferred to 100% acetone for 24 hr,
and stained in 0.015% Alcian Blue / 0.005% Alizarin Red in 0.8M acetic acid
and 70% ethanol for 24 hr. Remaining soft tissue was digested in 1% KOH
over 3 days, changing the solution daily, and skeletons were gradually trans-
ferred into 100% glycerol.
Lymphoma Transplants and Monitoring
Primary lymphomasweremechanically disrupted and passed through a 40 mM
filter to a single cell suspension. 2 3 105 viable cells were injected intrave-
nously into SCID mice pretreated with DOX for 24 hr. Peripheral blood was
stained with antibodies to CD45 (CD45-APC [30-F11, BD Pharmigen], CD4-
PECy5 [GK1.5, Biolegend], and CD8-PE [53-6.7, Biolegend]) and flow cytom-
etry was performed on a Guava HT EasyCyte and analyzed using InCyte
software (Guava Technologies). At necropsy, single cell suspensions from
spleen, bone marrow and peripheral LNs were analyzed by flow cytometry
as described above.
Cell Culture and Expression Analysis
ES cell cultures were selected and maintained on irradiated (40 Gy) MEFs
derived from the DR4 mouse strain (Tucker et al., 1997). To test ES cells for
luciferase knockdown, TG-luc.1309 ES cells were infected with MSCV-IRES-
luciferase and treated cells with 1 mg/ml DOX-hyclate (Sigma). For Trp53
protein blots in Figure 1, Figure 2, and Figure S1E, cells were treated with
0.5 mg/ml Adriamycin (Bedford Laboratories, OH) for 4h to induce Trp53. To
assess survival of ES cells following DNA damage, cells cultured with and
without DOX for 4 days were treated with Adriamycin (0.4–256 ng/ml) for
12 hr, stained with propidium iodide (1 mg/ml) and counted by flow cytometry
(Guava EasyCyte). MEF cultures and protein blotting were performed as
described previously (Dickins et al., 2005).
RNA Extraction and Quantitative Real-Time PCR
For quantitative analysis of mRNA levels, cDNA was generated from total
RNA using random primers and MultiScribe reverse transcriptase (Applied
Biosystems) and amplified by PCR with SYBR Green dye detection (Applied
Biosystems, Warrington UK). Primers were described previously (Kado
et al., 2008; Niwa et al., 2000; Takahashi and Yamanaka, 2006) and PCR
product detection was performed on the IQ5 iCycler (BioRad) under standard
conditions. For details of small RNA cloning see Supplementary information.
Lung Histopathology and Immunofluorescence
Adenoviral Cre was purchased from the University of Iowa Gene Transfer
Vector Core and 2.53 107 PFUwas administered to mice 4–6 wk of age (Jack-
son et al., 2001). Lung plucks were inflated with 10% buffered formalin and
embedded and stained according to standard protocols. For tumor burden
analyses (Figure 7E and Figure S7B), all lung lobes were orientated in the
same manner and 10 cross sections 100 mm apart were quantified using
NDP view software (Hamamatsu). For immunofluorescence, lungs were
flushed with ice cold PBS and filled with agarose via tracheal intubation.
Cooled, rigid tissue was sectioned on a Leica vibratome at 150 mm. Sections
were heated to remove agarose and fixed in 3.7% formaldehyde at RT. Lung
slices were permeabilized with 0.5% triton x-100, blocked with 1% BSA and
stained overnight at 4C. Specimens were counterstained with DAPI.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, two tables, and two movies and can be found with this article online at
doi:10.1016/j.cell.2011.03.012.
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